People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bluejay Therapeutics, Inc. | — | Pharma | Series D+ | $221.7M | $2.1B | 2024 |
Jianqing Li at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jianqing Li on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alon Lazarus | 1 | 7 |
| Nancy Hong | 1 | 4 |
| Wen Chen | 1 | 3 |
| William J. Rutter | 1 | 3 |
| Dan Estes | 1 | 3 |
| Ting J. Jia | 1 | 1 |
| Pascal Krotee | 1 | 1 |
| Keting Chu | 1 | 1 |
| Dajun Yang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.